Down almost 70% from all-time highs, Profound Medical is an undervalued growth stock that offers significant upside potential today. The post Opinion: This Is the Only TSX Growth Stock to Own for the ...

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Profound Medical Corp. remains rated Sell due to persistent competitive pressures, missed growth promises, and deteriorating financials. PROF's recent 20% stock spike followed news of a Dallas Medical ...

TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

Profound Medical (PROF) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

Profound anticipates total revenue for the fourth quarter of 2024 to be in the approximate range of $4.1 million to $4.2 million, representing year-over-year growth of between 105% and 110%, and ...

On August 8, Profound Medical presents Q2 figures. Analysts on Wall Street predict Profound Medical will release losses per share of $0.282. Follow Profound Medical stock price in real-time here.

BOSTON--(BUSINESS WIRE)--AcuityMD, the intelligence platform for the medical technology (MedTech) industry, has been selected by Profound Medical, a medical device company developing customizable, ...

Profound Medical PROF shares soared 9.5% in the last trading session to close at $8.34. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF) investors concerning the ...